Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins

HER2-positive breast cancer occurs in 15–20% of patients and is associated primarily with a poor prognosis the disease need for highly specific targeted therapy. Despite clinical importance determining HER2/neu, traditional diagnostic methods have their disadvantages require study new additional research techniques. The information presented this review makes it possible to consider current trends radionuclide diagnosis using latest class alternative scaffold proteins various aspects use practice.